348 results on '"Andreu, Jordi"'
Search Results
2. The role of oxidative stress in neurodegenerative diseases and potential antioxidant therapies
3. Experience and results after the implementation of a radiology day unit in a reference hospital
4. On-the-fly coarse-graining methodology for the simulation of chain formation of superparamagnetic colloids in strong magnetic fields
5. Aggregation of superparamagnetic colloids in magnetic fields: the quest for the equilibrium state
6. Towards a mathematical theory of meaningful communication
7. On Linguistic Creativity
8. Acquired tracheomalacia due to SARS‐CoV‐2 pneumonia.
9. PNPLA3 protein levels are increased in liver and decreased in adipose tissue from patients with obesity-associated non-alcoholic steatohepatitis
10. CT of pendular motion of the mediastinum
11. Supplementary Table 2 from A Pharmacodynamic/Pharmacokinetic Study of Ficlatuzumab in Patients with Advanced Solid Tumors and Liver Metastases
12. Supplementary Figure 3 from A Phase I Pharmacokinetic and Pharmacodynamic Study of Dalotuzumab (MK-0646), an Anti-Insulin-like Growth Factor-1 Receptor Monoclonal Antibody, in Patients with Advanced Solid Tumors
13. Supplementary Figure 2 from Phase I Pharmacokinetic/Pharmacodynamic Study of MLN8237, an Investigational, Oral, Selective Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors
14. Supplementary Figure 2 from A Phase I Pharmacokinetic and Pharmacodynamic Study of Dalotuzumab (MK-0646), an Anti-Insulin-like Growth Factor-1 Receptor Monoclonal Antibody, in Patients with Advanced Solid Tumors
15. Supplementary Table 3 from A Pharmacodynamic/Pharmacokinetic Study of Ficlatuzumab in Patients with Advanced Solid Tumors and Liver Metastases
16. Supplementary Figure 1 from Phase I Pharmacokinetic/Pharmacodynamic Study of MLN8237, an Investigational, Oral, Selective Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors
17. Supplementary Table 1 from A Pharmacodynamic/Pharmacokinetic Study of Ficlatuzumab in Patients with Advanced Solid Tumors and Liver Metastases
18. Supplementary Figure 3 from Phase I Pharmacokinetic/Pharmacodynamic Study of MLN8237, an Investigational, Oral, Selective Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors
19. Supplementary Figure 4 from Phase I Pharmacokinetic/Pharmacodynamic Study of MLN8237, an Investigational, Oral, Selective Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors
20. Supplementary Figure 5 from Phase I Pharmacokinetic/Pharmacodynamic Study of MLN8237, an Investigational, Oral, Selective Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors
21. Supplementary Figure 1 from A Phase I Pharmacokinetic and Pharmacodynamic Study of Dalotuzumab (MK-0646), an Anti-Insulin-like Growth Factor-1 Receptor Monoclonal Antibody, in Patients with Advanced Solid Tumors
22. Supplementary Tables 1 - 4 from Phase I Pharmacokinetic/Pharmacodynamic Study of MLN8237, an Investigational, Oral, Selective Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors
23. Supplementary Methods from Phase I Pharmacokinetic/Pharmacodynamic Study of MLN8237, an Investigational, Oral, Selective Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors
24. Data from Phase I Assessment of New Mechanism-Based Pharmacodynamic Biomarkers for MLN8054, a Small-Molecule Inhibitor of Aurora A Kinase
25. Supplementary Figure 2 from Phase I Assessment of New Mechanism-Based Pharmacodynamic Biomarkers for MLN8054, a Small-Molecule Inhibitor of Aurora A Kinase
26. Supplementary Tables 1-5 from Phase I Assessment of New Mechanism-Based Pharmacodynamic Biomarkers for MLN8054, a Small-Molecule Inhibitor of Aurora A Kinase
27. Supplementary Figure 1 from Phase I Assessment of New Mechanism-Based Pharmacodynamic Biomarkers for MLN8054, a Small-Molecule Inhibitor of Aurora A Kinase
28. Supplementary Figure Legends 1-2 from Phase I Assessment of New Mechanism-Based Pharmacodynamic Biomarkers for MLN8054, a Small-Molecule Inhibitor of Aurora A Kinase
29. TC de movimiento pendular del mediastino
30. Radiological findings of unilateral tuberculous lung destruction
31. Comparative assessment of image quality for coronary CT angiography with iobitridol and two contrast agents with higher iodine concentrations: iopromide and iomeprol. A multicentre randomized double-blind trial
32. The Lung Parenchyma: Radiological Presentation of Alveolar Pattern
33. Carnitine signature in liver corretales with non-alcoholic fatty liver disease progression
34. Hepatic lipid fingerprint reveals sex-dependent lipid droplet composition in metabolic associated fatty liver disease
35. Megafaunal assemblages in deep-sea ecosystems of the Gulf of Cadiz, northeast Atlantic ocean
36. Advancing fishery-independent stock assessments for the Norway lobster (Nephrops norvegicus) with new monitoring technologies
37. Exploration and discovery of sponge assemblages on the continental shelf and slope of the Catalano-Balearic Sea by means of non-invasive techniques
38. Estudi de viabilitat d'una proposta tècnica per millorar l'eficiència del sistema de climatització d'un mercat municipal
39. Intrapleural Fibrinolysis with Urokinase Versus Alteplase in Complicated Parapneumonic Pleural Effusions and Empyemas: A Prospective Randomized Study
40. Estudi de viabilitat d'una proposta tècnica per millorar l'eficiència del sistema de climatització d'un mercat municipal
41. Seguint la petja de Joan Solà
42. Histological Findings in Transbronchial Cryobiopsies Obtained From Patients After COVID-19
43. Statement on the conflict in Ukraine from the European Association of Psychosomatic Medicine
44. Histological Findings in Transbronchial Cryobiopsies Obtained From Patients After COVID-19
45. Lung Ultrasound as a First-Line Test in the Evaluation of Post-COVID-19 Pulmonary Sequelae
46. Persons with SARS-CoV-2 during the First and Second Waves in Catalonia (Spain): A Retrospective Observational Study Using Daily Updated Data
47. Clinical surrogate markers of survival in advanced non-small cell lung cancer (NSCLC) patients treated with second–third line erlotinib
48. XALOC, the MX beamline at ALBA synchrotron: current status and perspectives
49. Guia clínica per a l'atenció de les persones amb símptomes persistents de COVID-19
50. Llibres
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.